ArticleDermatology and therapy2026
Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTildrakizumab is an interleukin (IL)-23 p19 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis. This study assessed tildrakizumab effectiveness and drug survival in real-world patients with prior IL-17 inhibitor (IL-17i) experience.
methodsPatients initiated tildrakizumab (October 2018 to April 2024) at or after enrollment in the PPD™ CorEvitas™ Psoriasis Registry, an independent observational cohort of patients with psoriasis under dermatologist care in North America. Outcomes included drug survival from Kaplan-Meier analysis and changes from baseline in clinician- and patient-reported outcomes, including Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and patient-reported symptoms at 12 (± 3) months.
resultsOf 728 tildrakizumab initiators, 186 (25.5%) had prior IL-17i experience. Their mean age was 56.9 years; 54.3% were female, 137 (73.7%) had prior use of ≥ 2 biologics, including ≥ 1 IL-17i at any time, and 115 (61.8%) used an IL-17i immediately prior to tildrakizumab initiation. Over half (55.4%) had psoriatic arthritis at baseline. Baseline mean PASI was 6.0 (standard deviation [SD] (6.2) and mean DLQI was 7.2 (SD (6.8). The restricted mean tildrakizumab survival time was 27.4 months; 56.8% of initiators were persistent at 12 months. Improvements at 12 months were seen for PASI (mean 2.4, SD 4.8) and DLQI (mean 2.6, SD 5.7); 57.9%, 40.4%, and 38.9% of patients achieved PASI ≤ 3, PASI ≤ 1, and DLQI 0/1, respectively. Improvements in fatigue, skin pain, and itch were also observed.
conclusionsAs measured by clinician- and patient-reported outcomes, tildrakizumab was effective in real-world patients in North America with extensive prior biologic experience including immediate prior IL-17i experience. The majority of IL-17i-experienced initiators persisted on treatment for at least 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.